Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial †

By Tsai Hsiang-Lin   Tai Chi-Jung   Huang Ching-Wen   Chang Fang-Rong   Wang Jaw-Yuan  

Marine Drugs, Vol. 15, Iss. 4, 2017-04 ,pp. : 122-122

MDPI

Access to resources Recommend Favorite

Attitudes toward molecular testing for personalized cancer therapy

By Yusuf Rafeek A.   Rogith Deevakar   Hovick Shelly R. A.   Peterson Susan K.   Burton-Chase Allison M.   Fellman Bryan M.   Li Yisheng   McKinney Carolyn   Bernstam Elmer V.   Meric-Bernstam Funda  

Cancer, Vol. 121, Iss. 2, 2015-01 ,pp. : 243-250

Blackwell Publishing

Access to resources Recommend Favorite

Molecular Foundations for Personalized Therapy in Prostate Cancer

By  

Current Drug Targets, Vol. 16, Iss. 2, 2015-02 ,pp. : 103-114

Bentham Science Publishers

Access to resources Recommend Favorite

Bladder Cancer: Molecular Determinants of Personalized Therapy

By  

Current Drug Targets, Vol. 16, Iss. 2, 2015-02 ,pp. : 115-124

Bentham Science Publishers

Access to resources Recommend Favorite

Oxaliplatin: A Review of its Use in Combination Therapy for Advanced Metastatic Colorectal Cancer

By Simpson D.   Dunn C.   Curran M.   Goa K.L.  

Drugs, Vol. 63, Iss. 19, 2003-01 ,pp. : 2127-2156

Adis International

Access to resources Recommend Favorite